Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dirk Evers, Kevin Shianna, Mark McDonough

Premium

The New York Genome Center has appointed Dirk Evers and Kevin Shianna to its leadership team. Evers, who will serve as senior vice president of bioinformatics, joins NYGC from Illumina, where he led the company's computational biology efforts in the UK.

Shianna will serve as senior vice president of sequencing operations at the NYGC. He joins from Duke University, where he was an assistant professor in the School of Medicine, director of operations for the Center for Human Genome Variation, and founding director for the Genomic Analysis Facility.


CombiMatrix has named Mark McDonough its new chief commercial officer, effective immediately. McDonough has 20 years of experience in diagnostics sales and business development. Most recently, he was VP of sales, customer service, and training at Pathwork Diagnostics, and he spent six years at USLabs/Dianon, where he eventually became VP of sales.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.